Interleukin 2 Receptor Subunit Alpha Pipeline Review, H2 2019
Summary
Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA Interleukin2 receptor alpha is a protein that is encoded by the IL2RA gene. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells TREGs activity. TREGs suppress the activation and expansion of autoreactive Tcells.
Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA pipeline Target constitutes close to 12 molecules. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 3 and 5 respectively. Report covers products from therapy areas Immunology, Oncology, Cardiovascular, Dermatology and Metabolic Disorders which include indications NonSmall Cell Lung Cancer, Colorectal Cancer, Graft Versus Host Disease GVHD, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Melanoma, Plaque Psoriasis Psoriasis Vulgaris, Renal Cell Carcinoma, Solid Tumor, Systemic Lupus Erythematosus, Atopic Dermatitis Atopic Eczema, Autoimmune Disorders, Diabetic Nephropathy, Diffuse Large BCell Lymphoma, Gastric Cancer, Inflammation, Kidney Cancer Renal Cell Cancer, Kidney Transplant Rejection, Lung Cancer, Ovarian Cancer, Pulmonary Arterial Hypertension, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Relapsed Acute Myeloid Leukemia, Skin Cancer, Soft Tissue Sarcoma, Stroke, Transitional Cell Carcinoma Urothelial Cell Carcinoma and TripleNegative Breast Cancer TNBC.
The latest report Interleukin 2 Receptor Subunit Alpha Pipeline Review, H2 2019, outlays comprehensive information on the Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Scope
The report provides a snapshot of the global therapeutic landscape for Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA
The report reviews Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics and enlists all their major and minor projects
The report assesses Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Interleukin 2 Receptor Subunit Alpha TAC Antigen or p55 or CD25 or IL2RA development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope